13 minute read
Feb. 28, 2024

NaV1.8 Inhibitor Roundup: From Abbott to Vertex


NaV1.8, a member of the voltage-gated sodium channel (NaV) family, is predominantly expressed in peripheral sensory neurons. Based on rodent NaV1.8 knockout and knockdown studies and a 2012 report of gain-of-function mutations in humans, NaV1.8 has been linked to nociceptive, inflammatory, and neuropathic pain, including chronic neuropathic pain. Due to their early contributions in the mid-2000s, Abbott, Icagen, and Pfizer are recognized as early pioneers in the NaV1.8 inhibitor arena. Despite these discovery efforts, the translation of promising preclinical compounds into efficacious clinical candidates remained unrealized. VX-548 is now a notable exception, representing the only NaV1.8 inhibitor to achieve success in Ph. III clinical trials across various pain conditions. This compound roundup provides a historical recap of both preclinical and clinical NaV1.8 inhibitors that shaped the landscape for the new era of pain management we are witnessing today.



Other articles you may be interested in